Clinical trials: Intravenous Administration
Opioid Overdose
Pharmacokinetic (PK) Evaluation of Nalmefene Formulations
This study is designed to characterize the PK of nalmefene following IV bolus and IM injections using nalmefene 0.5 mg (0.94% MgCl2) and IV bolus of 0.5 mg nalmefene hydrochloride injection in healthy subjects.
- Trial name
- NCT07543276
- Testing
- Nalmefene + 0.94% MgCl2, Nalmefene Hydrochloride Injection
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Knoa Pharma LLC
Substance Use Disorders, Methamphetamine Abuse
A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
The purpose of this Phase 1a study is to evaluate safety, tolerability, and pharmacokinetics (PK) of single, ascending doses of CS-1103, administered by intravenous (IV) infusion in healthy participants.
- Conditions
- Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
- Trial name
- NCT06316973
- Testing
- CS-1103, Sterile Saline
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Clear Scientific, Inc.
Rheumatoid Arthritis
Phase 1b/2 Study of IV Sarilumab in Adult With RA
This is a Phase 1/Phase 2 study with: 5-arms design for Part A; and a single arm for Part B. The purpose of this study is to measure PK parameters and safety with sarilumab intravenous (IV) with or without concomitant oral…
- Trial name
- OPALS (NCT07704580)
- Testing
- Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Sanofi
Neoplasms, Malignant
A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusion to Patients With Advanced Solid Tumor
Primary Objectives: To determine the excretion balance and systemic exposure of radioactivity after intravenous infusion of [14C]-AVE8062 to humans To determine the pharmacokinetics of AVE8062 and RPR258063 and their contribution…
- Trial name
- NCT01063946
- Testing
- Ombrabulin (AVE8062)
- Where
- Belgium
- Volunteers
- 3 people
- Sponsor
- Sanofi
Malignant Solid Tumors
One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors
This is an open-label, dose-escalation and dose-expansion Phase I /II clinical study divided into Phase I and Phase II to evaluate the safety and tolerability of JCXH-211 combined with anti-PD-1 antibody in patients with…
- Trial name
- NCT06781125
- Testing
- JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion
- Volunteers
- 72 people
- Sponsor
- Immorna Biotherapeutics, Inc.
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Carcinoma, Small Cell, Small Cell Lung Cancer
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
The purpose of this study is to evaluate the objective tumor response rate to SNS-595 in patients with small cell lung cancer (SCLC).
- Trial name
- NCT00298896
- Testing
- SNS-595
- Where
- 17 sites in United States, Canada
- Volunteers
- 55 people
- Sponsor
- Sunesis Pharmaceuticals
Carcinoma, Squamous Cell of the Head and Neck
Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers
The purpose of this Phase 3 study is to evaluate overall survival and progression free survival following intravenous administration of REOLYSIN (Reovirus Serotype 3 Dearing) in combination with paclitaxel and carboplatin versus…
- Trial name
- NCT01166542
- Testing
- REOLYSIN, Carboplatin, Paclitaxel
- Where
- 77 sites in United States, Belgium and 11 more
- Volunteers
- 167 people
- Sponsor
- Oncolytics Biotech
Heart Failure
Efficacy and Safety of Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients.
The purpose of this study is to compare the effects of levosimendan with dobutamine on heart function in patients suffering of severe chronic heart failure.
- Trial name
- NCT00219388
- Testing
- Levosimendan
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Orion Corporation, Orion Pharma
Neoplasm
Radiation Dosimetry, Metabolism, Safety, Tolerability and Positron Emission Tomography/Computed Tomography (PET/CT) Imaging With BAY 85-8050 in Healthy Volunteers and Patients
This study is a visual assessment of diagnostic PET/CT images obtained after a single intravenous injection of BAY85-8050 in patients with cancer
- Trial name
- NCT00961831
- Testing
- F-18 (BAY85-8050)
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bayer
Candidiasis, Invasive, Candidemia
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
This is a multicenter, randomized, double-blind study of two treatment regimens for invasive candidiasis including candidemia. Subjects will receive intravenous echinocandin followed by oral ibrexafungerp (SCY-078) vs intravenous…
- Trial name
- MARIO (NCT05178862)
- Testing
- SCY-078, Fluconazole, Echinocandin
- Where
- 101 sites in United States, Belgium and 11 more
- Volunteers
- 68 people
- Sponsor
- Scynexis, Inc.
Dry Eye Syndrome, Systemic Lupus Erythematosus
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Sjorgren's disease (SjD) is a chronic, multisystem autoimmune disease characterized by lacrimal and salivary…
- Trial name
- NCT06977724
- Testing
- ABBV-319
- Where
- 11 sites in United States, France and 1 more
- Volunteers
- 36 people
- Sponsor
- AbbVie
Gout
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE)
This is a multicenter, randomized, double-blind, placebo-controlled phase II study assessing the efficacy, safety, and dosing regimen selection of multiple IV infusions of PRX-115 over 24 weeks, with or without MTX, versus the…
- Trial name
- RELEASE (NCT07280156)
- Testing
- PRX-115, Methotrexate (MTX)
- Where
- 35 sites in United States, Georgia and 1 more
- Volunteers
- 150 people
- Sponsor
- Protalix
Neoplasms
Weekly BI 836880 in Patients With Advanced Solid Tumors
This is a Phase I, multi-centre, non-randomized, uncontrolled, open-label, dose escalating study of BI 836880 administered intravenously once a week. The eligible patient population will be patients with advanced solid tumors.
- Trial name
- NCT02689505
- Testing
- BI 836880
- Where
- 2 sites in France, Spain
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
Huntington Disease
Dose-response Evaluation of the Cellavita HD Product in Patients With Huntington's Disease
Cellavita HD is a stem-cell therapy for Huntington's Disease. This is a prospective, phase II, single-center, randomized (2:2:1), triple-blind, placebo controlled study, with two test doses of Cellavita HD product.
- Trial name
- ADORE-DH (NCT03252535)
- Testing
- Cellavita HD lower dose, Cellavita HD higher dose
- Where
- Brazil
- Volunteers
- 49 people
- Sponsor
- Azidus Brasil
Myelogenous Leukemia, Acute
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01641250
- Testing
- RO5429083, cytarabine
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Neoplasms
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of the combination of BI 6727 with BIBW 2992, in patients with advanced or metastatic solid…
- Trial name
- NCT01206816
- Testing
- BI 6727 + BIBW 2992
- Where
- 3 sites in Belgium
- Volunteers
- 57 people
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease
A Trial of SHR-1707 in Healthy Young Adult and Elderly Subjects
A randomized, double-blind, placebo-controlled, single dose escalation phase 1 study to access the Pharmacokinetics and Pharmacodynamics of Single Intravenous Administration of SHR-1707
- Trial name
- NCT04745104
- Testing
- SHR-1707
- Where
- Australia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Atridia Pty Ltd.
Healthy
A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.
The purpose of this First-in-Human study is to evaluate the safety , tolerability and pharmacokinetics after single ascending of HNC042 given to healthy subjects, compared to placebo.
- Trial name
- NCT03740555
- Testing
- HNC042 single dose, HNC042 multiple ascending doses
- Where
- United States
- Volunteers
- 74 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Cancer
Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV Administration in Subjects With Relapsed or Refractory Solid Tumors
To determine the safety, tolerability, and the highest dose of this drug given once every 3 weeks or once every week, (per 21 day cycle) in adult subjects with relapsed or refractory solid tumors.
- Trial name
- MEDI-547 (NCT00796055)
- Testing
- MEDI-547
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- MedImmune LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.